Loading company…
Seongnam-based MEDIPOST develops stem cell therapies, including CARTISTEM for knee cartilage defects.
MEDIPOST Co., Ltd. was founded in 2000 in Seongnam, South Korea, and specializes in biotechnology focused on stem cell therapies. Its first-generation products include CARTISTEM for knee cartilage defects in osteoarthritis patients and PNEUMOSTEM for bronchopulmonary dysplasia, and its second-generation candidates include SMUP-IA-01 and SMUP-IV-01. Products are aimed at healthcare providers and hospitals in South Korea. In January 2026, Crescendo Equity Partners and SkyLake Equity Partners acquired convertible bonds for KRW 150 billion in a PIPE transaction, and CEO Won-il Oh leads the company.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in